Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06168487 | Telmisartan in Prostate Cancer | recruiting | Phase 1 | 36 | Tyler J CurielOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06274047 | PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | recruiting | Phase 3 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 22, 2026 |
| clinicaltrials |
| NCT06678828 | Clinical Utility of ClarityDX Prostate | enrolling by invitation | N/A | 1,450 | NanosticsINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07278362 | Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance | not yet recruiting | Phase 4 | 35 | University of MiamiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04254133 | Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study(GIFTS) | enrolling by invitation | — | 1,360 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04751435 | Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients(IMAGINE) | recruiting | N/A | 445 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05416996 | A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer | active not recruiting | — | 88 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06039371 | Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | recruiting | Phase 2 | 69 | University of WashingtonOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06183905 | Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection(TRUSVSMPMRI) | active not recruiting | N/A | 635 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | recruiting | Phase 3 | 520 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 6 | Jul 21, 2026 | clinicaltrials |
| NCT07221825 | Low-Count Quantitative SPECT for Men Treated With Radium-223 | recruiting | N/A | 38 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07302451 | REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)(REDI-CaP) | recruiting | Phase 2 | 50 | National Cancer Institute, NaplesOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07426055 | PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer(PRO-BOOST-LC) | recruiting | Phase 2 / Phase 3 | 1,000 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07426094 | PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer(PRO-BOOST-N) | recruiting | Phase 2 / Phase 3 | 600 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07707232 | Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports(PSMA-LLM-cTNM) | recruiting | — | 4,600 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04545957 | Jump: MR Simulation For Radiation Therapy Master Protocol(JUMP) | recruiting | N/A | 86 | Brigham and Women's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07694752 | MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology | recruiting | — | 80 | Jiangsu Taizhou People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04857502 | 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy(EXCALIBUR) | active not recruiting | Phase 2 | 165 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06067269 | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial(HEATWAVE) | recruiting | Phase 2 | 95 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710807 | Transperineal Versus Transrectal Cognitive Fusion Prostate Biopsy(PROCOG) | recruiting | N/A | 280 | Ankara Etlik City HospitalOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03999151 | Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II) | active not recruiting | N/A | 204 | University of California, San FranciscoOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07365423 | Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)(TerbinaPro) | recruiting | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709338 | Targeted Biopsy, Rapid Pathology, and Immediate Surgery in USTC High-Risk Prostate Cancer: A Prospective Multicenter Study | not yet recruiting | N/A | 150 | Anhui Provincial HospitalOTHER_GOV | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07709403 | Radioactive Counts From PSMA PET/CT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study | not yet recruiting | — | 20 | Peking University First HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT04267887 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05918263 | Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial | recruiting | N/A | 68 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06066437 | NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial | recruiting | Phase 1 / Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07258563 | The TASTY-steering Study(TASTY-steering) | recruiting | N/A | 201 | University Medical Center GroningenOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04420702 | Diffusion Basis Spectrum Imaging of the Prostate | recruiting | N/A | 500 | Washington University School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05169970 | A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer | active not recruiting | Phase 2 | 222 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05568550 | Pembro With Radiation With or Without Olaparib | recruiting | Phase 2 | 64 | Zin W MyintOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05842057 | Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy(HAMMER) | active not recruiting | Phase 2 | 118 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials GroupNETWORK | 4 | Jul 14, 2026 | clinicaltrials |
| NCT06865768 | An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique | recruiting | Phase 2 | 90 | Emory UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702864 | Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention(CHEF) | not yet recruiting | N/A | 40 | University of ArizonaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT00868803 | Aberrant Gene Expression Prostate Carcinoma | active not recruiting | — | 5,000 | Lahey ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT03802851 | HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer(HOLEP-RTPC) | recruiting | N/A | 30 | University of Kansas Medical CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04748042 | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | active not recruiting | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 216 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06037954 | A Study of Mental Health Care in People With Cancer | recruiting | N/A | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials